P1.03-07 A Comparison of Consistency of Detecting HER2 Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients

C. Xu,W. Wang,Q. Zhang,Y. Zhu,W. Zhuang,Y. Huang,Y. Chen,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2018.08.688

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:HER2 is expressed in solid carcinomas including cancers of the breast, stomach, lung and pancreas. Preclinical and clinical studies have confirmed that HER2 is a driver gene in non-small-cell lung cancer (NSCLC). Three principal mechanisms of HER2 alteration include: protein overexpression, gene amplification and gene mutations. In NSCLC, HER2 mutations were identified to represent a distinct subset of driver genes that usually excluded with other common driver genes like EGFR, KRAS and ALK, based on published studies. The aim is to detect the consistency of the HER2 gene mutation in peripheral blood and tumor tissue of patients with NSCLC and discuss the clinical application value of HER2 gene mutation in peripheral blood. Real-time fluorescent quantitative PCR was used to determine the HER2 gene mutation of peripheral blood and tumor tissue specimens collected from 185 cases of NSCLC. A comparison of HER2 gene mutation consistency of peripheral blood and tumor tissue specimens was conducted. The correlation between HER2 gene mutations and clinical characteristics of the patients was analyzed. The HER2 gene mutation rate was 3.78% in peripheral blood of 7 patients with NSCLC, and was 2.16% in 4 cancer tissues, the mutation consistency was 75.00% in peripheral blood tumor tissue matched samples. The consistency was statistically significant (κ=0.553, P<0.001). The incidence of HER2 gene mutation in peripheral blood correlate with smoking history (P<0.05), but did not correlate with age, gender and pathological type (P>0.05). The incidence of HER2 gene mutation in tumor tissue correlated with gender and smoking history (P<0.05), but did not correlate with age and pathological type. The consistency of the HER2 gene mutation in peripheral blood and tissue is high. HER2 gene mutations of peripheral blood could be used for clinical diagnosis and treatment in cases when tissue specimen is hard to get.